Trastuzumab deruxtecan: heralding biomarker-directed therapy in metastatic colorectal cancer
- PMID: 33961794
- DOI: 10.1016/S1470-2045(21)00186-8
Trastuzumab deruxtecan: heralding biomarker-directed therapy in metastatic colorectal cancer
Conflict of interest statement
IC sits on advisory boards of Eli-Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, Merck-Serono, Five Prime Therapeutics, Astra-Zeneca, OncXerna, Pierre Fabre, Boehringer Ingelheim, Incyte, and Astella. IC reports research funding from Eli-Lilly and Janssen-Cilag, and honoraria from Eli-Lilly and Eisai. IC thanks the NHS for funding the National Institute for Health Research Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research.
Comment on
-
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.Lancet Oncol. 2021 Jun;22(6):779-789. doi: 10.1016/S1470-2045(21)00086-3. Epub 2021 May 4. Lancet Oncol. 2021. PMID: 33961795 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
